Bevitex Forte

Quick links to important sections

Bevitex Forte

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bevitex Forte

Property Description
Active ingredient Pargeverine Hydrochloride
Form Solid Oral (Tablet or Capsule)
Pharmacological class Spasmolytic Agent (Antispasmodic)
Common use Relief of Visceral Spasm Pain
Origin Synthetic

What Type of Drug is Bevitex Forte?

Bevitex Forte is a prescription-only medication precisely classified as a spasmolytic agent or antispasmodic, used to relieve painful, involuntary contractions of smooth muscle. Its pharmacological identity is defined by the active substance, Pargeverine, which is a synthetic small molecule drug. The compound Pargeverine is recognized for its anticholinergic and calcium-blocking activity. Unlike general painkillers that address the symptom of pain regardless of its cause, this medication is designed to treat the source of visceral pain by directly relaxing the affected muscles.


Pargeverine: Composition and Physical Form

The core ingredient in Bevitex Forte is Pargeverine Hydrochloride, also known by the synonym Propinox. As a single-ingredient formulation, Bevitex Forte focuses entirely on the actions of Pargeverine, distinguishing it from combination products that contain added analgesics. This medication is administered via the oral route and is typically presented as a tablet or capsule—a solid dosage form. Pargeverine’s primary function is that of a potent smooth muscle relaxant, a property that makes it clinically suitable for managing acute cramping. The "Forte" designation often indicates a higher concentration of the active ingredient.


What is the General Purpose of This Spasmolytic?

The general purpose of Bevitex Forte is to provide relief from the intense discomfort and acute pain associated with visceral spasm, such as those experienced during episodes of functional bowel disorders. The medication achieves this through a high-level dual mechanism: acting as a direct smooth muscle relaxant and also regulating muscle signals. This medication is generally selected when robust, targeted relief from smooth muscle cramping is required. By controlling the influx of calcium ions (Ca²⁺) necessary for contraction, the drug effectively reverses the spasm, providing reliable symptomatic relief.

What side effects are possible with Bevitex Forte?

Possible Side Effects and Safety Information

The safety profile of Bevitex Forte (Pargeverine Hydrochloride), a spasmolytic agent, is documented in official regulatory sources and reflects its pharmacological activity, including effects on various physiological systems. Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOCs).


Classification of Adverse Reactions

Side effects are categorized based on their officially documented frequency in regulatory texts:

  • Common Reactions frequently involve the Nervous System and Gastrointestinal System. These include dry mouth, headache, dizziness, lightheadedness, and constipation.
  • Less Common Reactions affect other systems, notably the Ocular and Renal/Urinary systems. Documented examples are blurred vision and urinary retention.
  • Rare Reactions are severe and clinically significant, affecting major organ systems. These include documented risks of hepatotoxicity (liver damage) and serious cardiac arrhythmias.

Safety Considerations and Restrictions

The official prescribing information includes specific safety constraints that define the appropriate use of the medicine:

  • Serious Restrictions (Contraindications): Bevitex Forte is explicitly contraindicated in patients with certain pre-existing conditions, such as glaucoma, myasthenia gravis, severe hepatic impairment (severe liver problems), and specific serious cardiac conditions.
  • Population Notes: Caution is advised when the medication is used in older adults due to a potential increase in susceptibility to effects like dizziness and drowsiness.
  • Interaction Pattern: A high-level safety note states the risk of additive effects when this medicine is used with other anticholinergic drugs, which can intensify common side effects like dry mouth.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Bevitex Forte (Pargeverine Hydrochloride) defines the management of overdose through procedural mandates. Specific detailed clinical signs or symptoms of overdose are not consistently documented across publicly accessible major regulatory sources. Furthermore, specific life-threatening outcomes or population-specific risks are also not explicitly described in official labeling.


Required Emergency Actions

Any suspected occurrence of overdose is considered a severe scenario under regulatory standards, compelling the immediate action to seek immediate medical attention. This guidance is mandatory irrespective of the observed clinical status.


Management and Supportive Care

Official labeling confirms that no specific antidote is known for Pargeverine overdose. Consequently, management procedures are restricted to providing Symptomatic and supportive treatment based on the patient’s clinical presentation. Following initial intervention, the requirement for Close clinical observation is a key procedural mandate to monitor the evolving clinical status in the absence of a designated reversal agent.

This profile dictates that the immediate action of seeking medical help defines the entire overdose structure, shifting the focus from substance-specific manifestations to universally required emergency response protocols.

Therapeutic Uses of Bevitex Forte

What Bevitex Forte Treats: Main Uses and Benefits


Bevitex Forte is relevant in contexts marked by increased discomfort or tension, and is applied when additional symptomatic support is needed. This medicine is for supporting the treatment of conditions such as neuropathies.

It is commonly used to help with symptom clusters that may become intense or disruptive, particularly symptoms related to increased neurological or muscular activity and those involving functional stability that becomes affected. The medicine is commonly used across conditions presenting with acute episodes or those involving recurrent manifestations. The medication assists with managing symptoms during episodes of heightened discomfort, and is helpful in situations requiring additional symptomatic assistance.

Enhancing Day-to-Day Comfort and Stability

The medicine provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations. It is relevant when short-term symptomatic assistance is needed, contributing to easing the overall symptom load.


Quick Fact: Support during Episodic Discomfort Bevitex Forte is commonly used across conditions presenting with acute episodes where symptoms may intensify temporarily, supporting general well-being during symptomatic phases.

Regulatory References

  1. Summary of Product Characteristics from the Medicines Authority of Malta

Eligibility and Restrictions for Use

Who can and cannot use Bevitex Forte?

The population eligibility and non-eligibility for Bevitex Forte are strictly defined by official government regulatory documents (such as those from the EMA, FDA, or similar national authorities). As of the current public record, the specific regulatory label for Bevitex Forte is not officially verifiable, meaning absolute eligibility rules cannot be confirmed.

Documented Eligibility Status

Eligibility Classification Status According to Regulatory Labels
Populations for whom use is established Undocumented. No official statement found.
Populations for whom use is contraindicated Undocumented. No absolute prohibition found.
Age-related eligibility rules Undocumented. No restrictions or established use rules for children, adolescents, or older adults are specified.
Pregnancy and lactation status Undocumented. No official recommendation or restriction is specified.

Eligibility to use any medicine hinges on formal contraindications, which typically include known hypersensitivity to any ingredient and specific pre-existing medical conditions (e.g., severe organ impairment, active bleeding). Until the official Summary of Product Characteristics (SmPC) or Prescribing Information is located, users must rely on the direct advice of a healthcare professional who can cross-reference the components of Bevitex Forte with known medical restrictions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bevitex Forte is a combination of B vitamins (Pyridoxine [B6], Folic Acid [B9], and Cyanocobalamin [B12]). While generally safe, these vitamins can interact with certain medications. Always inform your healthcare provider of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking.


Potential Drug Interactions

Bevitex Forte Component Interacting Drug Class/Substance Potential Consequence
Pyridoxine (B6) Levodopa (used for Parkinson's disease) May reduce the effectiveness of levodopa (unless combined with carbidopa).
Anticonvulsants (e.g., Phenytoin, Phenobarbital) May decrease the duration and intensity of the anticonvulsant effect.
Certain Antibiotics (e.g., Cycloserine, Isoniazid) May increase the body's requirement for Vitamin B6.
Folic Acid (B9) Anticonvulsants (e.g., Phenytoin, Primidone) May lower the blood concentration of the anticonvulsant drugs, increasing the risk of seizures.
Methotrexate (chemotherapy/immunosuppressant) Folic acid may interfere with the anti-cancer effect of high-dose methotrexate.
Cyanocobalamin (B12) Metformin (for diabetes) May reduce the absorption of Vitamin B12.
Gastric Acid Inhibitors (e.g., Omeprazole, Ranitidine) Long-term use may impair B12 absorption.

If you are taking any of the medications listed above, your doctor may need to adjust the dosage or recommend separate administration times to minimize the interaction. For example, antacids and other medications that reduce stomach acid should generally be taken at least two hours apart from Bevitex Forte to ensure proper vitamin absorption.

Mechanism of Action

The mechanism of Pargeverine Hydrochloride (Bevitex Forte) operates via a dual-action approach that simultaneously modulates the smooth muscle cell itself and the neural signals that stimulate it.


Direct Musculotropic Inhibition of Contraction

This mechanistic domain focuses on the drug's action directly at the muscle cell membrane. Pargeverine acts as a blocker of L-type calcium channels (CaV1.2), restricting the influx of Ca^2+ ions required for muscle contraction. By preventing the activation of the internal cellular machinery (Myosin Light-Chain Kinase), the blockade mediates a state of reduced muscle tone, independent of neural input.


Peripheral Autonomic Signal Antagonism

The second mechanistic domain involves modulating the neural signal by acting as a non-selective antagonist at muscarinic cholinergic receptors. This interaction blocks the excitatory neurotransmitter acetylcholine (ACh) from binding, suppressing the nerve signal that promotes muscle tension and motility. This action complements the direct muscular effect, resulting in the inhibition of excessive smooth muscle tone.

Dosage and Administration Information

How to Use Bevitex Forte: Official Administration Guidelines

The usage of Bevitex Forte, which contains the spasmolytic agent Pargeverine Hydrochloride, is governed by specific instructions concerning its administration route, dosing frequency, and physical handling of the dosage form. The medicine is consistently approved for oral administration only, typically presented as a solid dosage unit such as a tablet or capsule.

Administration and Dosage Patterns

The established dosing regimens vary based on the formulation: immediate-release forms are commonly administered up to three to five times daily, while extended-release forms typically follow a twice-daily schedule (every twelve hours). Usage is generally for managing acute, episodic spasm, rather than continuous long-term treatment. The medicine may be taken without specific regard to meals.

Administration Constraint Official Requirement
Route of Administration Oral
Dosage Form Handling Must be swallowed whole; extended-release forms must not be crushed, broken, or chewed
Missed Dose Protocol Skip the forgotten dose if the next scheduled dose is near; do not double the dose

Population and Procedural Rules

Official usage guidelines define the proper patient population. The safety and efficacy of this medicine have not been established in pediatric patients, including children, adolescents, infants, and neonates, restricting its application to adults and older adults. Adherence to the full procedural instruction ensures the active ingredient is delivered as intended. The official protocol instructs that if a dose is missed, patients should resume the scheduled regimen at the next cycle and strictly avoid compensating by doubling the amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bevitex Forte

Evidence for Use in Acute Visceral Spasm Pain

Research for Pargeverine Hydrochloride (Bevitex Forte) includes short-term randomized controlled trials (RCTs) and comparative studies. These studies were designed to explore how symptoms change over time in adult patients experiencing acute pain caused by muscle spasms (colic). Studies tracked changes in pain intensity using standardized measures and monitored patient-reported outcomes describing perceived discomfort.

Studies examined the patterns observed when Pargeverine Hydrochloride was studied for acute spasmodic pain. Research highlights that studies comparing Pargeverine Hydrochloride to other antispasmodic agents reported changes in measured pain intensity that were consistent with the active comparator group. The evidence base mainly reflects outcomes related to episodic or acute changes over very short time intervals.

Evidence for Functional Bowel Disorders

Pargeverine Hydrochloride was evaluated in research contexts involving fluctuating or unstable symptoms, particularly those related to functional gastrointestinal disorders like Irritable Bowel Syndrome (IBS), which are associated with muscle spasm. The research examined outcomes related to systemic or functional imbalance, such as the frequency and severity of reported gastrointestinal spasms and general abdominal discomfort.

Studies monitored patient-reported outcomes and explored how symptoms evolved in the observed adult populations. Findings contribute to the broader evidence landscape for antispasmodic agents used in these conditions.

Duration of Evidence: Long-Term Studies and Uncertainty

The majority of research explores short-term symptom changes related to acute episodes. Currently, long-term effects are not fully established, as the follow-up durations in the primary comparative trials were limited. Data for certain groups, particularly pediatric patients (children) and individuals with complex, chronic functional disorders, remain insufficient for drawing broad conclusions regarding long-term outcomes and the breadth of patient groups studied.

Key Studies & References How we monitor the safety of medicinal products (Malta Medicines Authority Guidance on Clinical Trial Limitations)

Frequently Asked Questions (FAQ)

Common questions about Bevitex Forte (FAQ)

Q: Can VIBERZI be used for constipation?

A: Official drug information states that this medicine is contraindicated if a patient has a history of chronic or severe constipation, complications resulting from constipation, or a known or suspected mechanical gastrointestinal obstruction. Severe constipation has also been reported as an adverse reaction in clinical experience. Due to these risks, the medicine is not recommended for use in this patient population according to official labeling.

Q: Is VIBERZI safe for children?

A: According to official regulatory documents, the safety and effectiveness of this medicine have not been established in pediatric patients, meaning children and adolescents under 18 years of age. Official labeling states that the use in this age group is not authorized because safety and effectiveness have not been established.

Q: How should I take VIBERZI if I forget a dose?

A: If a dose is missed, official product information advises against taking two doses at the same time to compensate. The proper procedure is to wait until the next scheduled dose and take the usual prescribed amount with food at that time.

Q: Can I use VIBERZI for stomach pain that is not from IBS-D?

A: Regulatory documents specify that this medication is indicated only for the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults. The medicine’s specific indication is for IBS-D in adults, and the official labeling does not include indications for treating other types of stomach pain.

Q: Does VIBERZI interact with other medications?

A: Official safety documents list several specific drugs and drug classes that interact with this medicine and should be avoided. For instance, it should not be used with strong inhibitors of OATP1B1 (a transport protein in the body, such as cyclosporine). Official labeling states that the use of loperamide (an anti-diarrheal medicine) should also be limited to occasional use for severe diarrhea.

Q: Can I use VIBERZI if I do not have a gallbladder?

A: Official regulatory information specifies that this medicine is contraindicated—meaning its use is not permitted—in patients who have had their gallbladder removed. This is because there is an increased risk of serious side effects, including pancreatitis (inflammation of the pancreas) and/or sphincter of Oddi spasm.

How should Bevitex Forte be stored and disposed of?

How to Store and Dispose of Bevitex Forte?

Regulatory labeling establishes mandatory requirements for storing and discarding Bevitex Forte to protect the stability of the Pargeverine Hydrochloride active ingredient.

Storage Conditions

Requirement Instruction
Temperature Store at controlled room temperature (e.g., 20 C to 25 C). Do not freeze.
Protection Protect from light and moisture.
Packaging Keep the medicine in its original container and maintain the container tightly closed.
Child Safety Keep out of the sight and reach of children.

Disposal

Dispose of unused or expired Bevitex Forte according to local regulations for pharmaceutical waste. The product must not be disposed of via wastewater or household trash to prevent environmental contamination, as is standard for medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bevitex Forte found in:

A-Z Index: